00:00It's been a really dramatic decline for Moderna since the peak of the pandemic. I mean, sales of their COVID vaccine has really declined. And so the company is really in cost cutting mode now. They're cutting back on research, manufacturing that they're not using, cutting jobs and just really trying to stabilize the business because COVID vaccines are going down year over year, about 30 percent this year.
00:24The stock is down 67 percent in five years. I thought that mRNA was going to help us like cure cancer. What happened to this miraculous technology? I think that's what a lot of Moderna investors are hoping for. In a few years, Moderna says that they could get approved for a vaccine for cancer. So people who have melanoma could get this treatment.
00:49And it's an individual treatment for them using mRNA technology. It's a program that Moderna has partnered with Merck on. So investors are really hoping if the company could just hang on for a few more years that this is a real, you know, has a lot of potential.
01:02What's the timeline? How long till we do get that vaccine? I mean, after RFK, obviously, it's out of.
01:08It depends on cases. But I mean, Moderna has said that potentially by 2027, this cancer treatment could be on the market. So that's really what investors are hoping for.
01:18In the meantime, they're very much dependent on their COVID vaccine and that's declining. Their RSV vaccine has not taken off the way that, you know, the company had thought it would.
Be the first to comment